Complex roles for reactive astrocytes in the triple transgenic mouse model of Alzheimer disease
MESH: Signal Transduction
STAT3 Transcription Factor
0301 basic medicine
MESH: Hippocampus
MESH: Mice, Transgenic
JAK-STAT3 pathway
[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
Amyloidogenic Proteins
Mice, Transgenic
tau Proteins
Hippocampus
MESH: Janus Kinase 2
03 medical and health sciences
Neuroinflammation
Alzheimer Disease
Animals
MESH: Animals
SOCS3
Phosphorylation
MESH: Amyloidogenic Proteins
MESH: Phosphorylation
Neuroinflammation.
MESH: STAT3 Transcription Factor
Janus Kinase 2
MESH: tau Proteins
3. Good health
MESH: Astrocytes
Disease Models, Animal
Astrocytes
Reactive astrocytes
Alzheimer disease
Tau
MESH: Disease Models, Animal
MESH: Alzheimer Disease
Signal Transduction
DOI:
10.1016/j.neurobiolaging.2020.02.010
Publication Date:
2020-02-19T00:38:18Z
AUTHORS (16)
ABSTRACT
ABSTRACTIn Alzheimer disease (AD), astrocytes undergo complex changes and become reactive. The consequences of this reaction are still unclear. To evaluate the net impact of reactive astrocytes in AD, we recently developed viral vectors targeting astrocytes that either activate or inhibit the JAK2-STAT3 pathway, a central cascade controlling astrocyte reaction.We aimed to evaluate whether reactive astrocytes contribute to Tau as well as amyloid pathologies in the hippocampus of 3xTg-AD mice, an AD model that develops Tau hyperphosphorylation and aggregation in addition to amyloid deposition. JAK2-STAT3 pathway-mediated modulation of reactive astrocytes in the hippocampus of 3xTg-AD mice, did not significantly influence Tau phosphorylation or amyloid processing and deposition, at early, advanced and terminal stage of the disease. Interestingly, inhibition of the JAK2-STAT3 pathway in hippocampal astrocytes did not improve short-term spatial memory in the Y maze but it reduced anxiety in the elevated plus maze. Our unique approach to specifically manipulate reactive astrocytes in situ show these cells may impact behavioral outcomes without influencing Tau or amyloid pathology.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (27)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....